

# Cardiol Therapeutics

09:59 01 Apr 2020

## Cardiol Therapeutics shares positive new study results supporting lead drug's ability to protect against heart failure

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) announced positive results from a new study that highlighted its cannabidiol formulation's ability to combat heart failure.

The study found that Cardiol's cannabidiol formulation significantly reduced myocyte hypertrophy in a model of non-ischemic heart failure.

Additional results showed a dose-dependent reduction of key inflammation markers, decreases in fibrosis, and lower B-type Natriuretic Peptide (BNP) expression, which is widely used to indicate the severity of heart failure.

### READ: Cardiol Therapeutics expecting significant growth in 2020 with launch of its pharmaceutical cannabidiol formulation in Canada

Results indicate that Cardiol's cannabidiol reduced the amount of BNP released, supporting its formulation as a cardioprotective therapy, the Toronto-based company told shareholders.

Cardiol's cannabidiol formulation, CardiolRx, is a pharmaceutically produced, THC-free (5ppm), highly concentrated product being developed to fight cardiac diseases.

The positive data supports the firm's plans for its Phase 2 trial looking at acute myocarditis, an inflammatory form of heart failure. The current study results support the anti-inflammatory and anti-fibrotic activity of Cardiol's cannabidiol formulation when it comes to heart failure.

Data submitted by its research collaborators was showcased at the American College of Cardiology's 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually from March 28-30.

"The data accepted for presentation at the ACC underscore the importance of Cardiol's research initiatives aimed at developing novel therapeutic strategies to address the devastating consequences of heart failure," stated David Elsley, Cardiol's CEO.

"The data also support our long-standing view concerning the powerful anti-inflammatory, anti-fibrotic, and cardioprotective properties of pharmaceutically produced cannabidiol, and serve as an encouraging scientific foundation for our planned international trial in acute myocarditis," he added.

Cardiol plans to develop its cannabidiol formulation to treat chronic heart failure, a major healthcare burden in North America, costing the US healthcare system over US\$30 billion a year.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

**Price:** 2.37

**Market Cap:** \$77.7 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** CRDL

**Listing:** TSX

**52 week High Low**  
5.4 1.87

**Sector:** Pharma & Biotech

**Website:** [www.cardiolrx.com](http://www.cardiolrx.com)

#### Company Synopsis:

Cardiol Therapeutics (TSX: CRDL; OTCQX: CRTPF) produces pharmaceutical cannabidiol and develops innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. Their lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, THC free (<math>\leq 5\text{ ppm}</math>), and formulated to be one of the safest and most consistent cannabidiol formulations.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).